BridgeBio Pharma Total Non-Operating Income/Expense 2018-2024 | BBIO

BridgeBio Pharma total non-operating income/expense for the twelve months ending September 30, 2024 was $0.098B, a 252.51% decline year-over-year.

  • BridgeBio Pharma annual total non-operating income/expense for 2023 was $-0.046B, a 266.54% decline from 2022.
  • BridgeBio Pharma annual total non-operating income/expense for 2022 was $0.028B, a 380.49% decline from 2021.
  • BridgeBio Pharma annual total non-operating income/expense for 2021 was $-0.01B, a 68.32% decline from 2020.

BridgeBio Pharma Total Non-Operating Income/Expense 2018-2024 | BBIO

  • BridgeBio Pharma annual total non-operating income/expense for 2023 was $-0.046B, a 266.54% decline from 2022.
  • BridgeBio Pharma annual total non-operating income/expense for 2022 was $0.028B, a 380.49% decline from 2021.
  • BridgeBio Pharma annual total non-operating income/expense for 2021 was $-0.01B, a 68.32% decline from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M